Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers

• Published in: American journal of respiratory and critical care medicine Vol. 150; no. 2; p. 469
• Main Authors: Davila, D G, Hurt, R D, Offord, K P, Harris, C D, Shepard, Jr, J W
• Format: Journal Article
• Language: English
• Published: United States 01.08.1994
• Subjects: Administration, Cutaneous; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine - administration & dosage; Nicotine - adverse effects; Nicotine - therapeutic use; Sleep - drug effects; Sleep Apnea Syndromes - drug therapy; Smoking; Snoring - drug therapy
• ISSN: 1073-449X
• DOI: 10.1164/ajrccm.150.2.8049831

Previous research has suggested that nicotine may be therapeutically useful in the treatment of sleep-disordered breathing. The development of transdermal nicotine delivery systems has allowed us to test the overnight effectiveness of nicotine. Twenty nonsmoking subjects (10 men, 10 women) were recruited on the basis of a history of habitual snoring that was confirmed by overnight laboratory monitoring. Subjects were then randomized (double-blind crossover design) to receive either placebo or an active patch that delivers 11 mg of nicotine over a 24-h period. Patches were applied at 6 P.M. and removed at 6 A.M. the following morning, at which time venous blood was obtained for determination of serum nicotine concentrations. Polysomnography was performed using standard techniques to assess sleep architecture and sleep-disordered breathing. Snoring was monitored with a sound-level meter and quantitatively analyzed to determine the snoring index (SI) (number of snores per hour of sleep) and mean and maximum snoring intensities. The age of the subjects was 46.9 +/- 11.4 yr (mean +/- SD) and their mean body mass index (BMI) 33.3 +/- 4.6 kg/m2. A mean nicotine level was nondetectable with placebo and 7.8 +/- 2.3 ng/ml with wearing of an active patch. Nicotine decreased total sleep time (TST) by 33 min (p < or 0.01), sleep efficiency from 89.7 to 83.5% (p < or = 0.01), and percent rapid eye movement (REM) sleep from 18.8 to 15.1% (p < or = 0.01), and prolonged initial sleep latency (ISL) from 6.7 to 18.2 min (p < or = 0.01).